COVID-19 Vaccination Tracker: Daily Rates, Statistics & Updates
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Covid-19 Vaccination Tracker

Latest news, statistics, daily rates and updates

Last updated 26 November, 2021 10:30 CEST

As the coronavirus vaccine rolls out across the globe, our world Covid-19 vaccine tracker will help you discover the latest Covid-19 updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

7,875,897,403

+28,301,216 reported yesterday

Number of fully vaccinated globally

3,356,580,845

+10,344,655 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

44.2%

+0.3% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda. View the latest Covid-19 Vaccine Statistics below.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 7,875,897,403 1,037.1 44.2%
China 2,472,847,000 1,775.5 77.3% CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 1,210,758,081 895.1 31.8% Covaxin, Oxford/AstraZeneca, Sputnik V
United States 454,447,737 1,389.0 59.5% Johnson&Johnson, Moderna, Pfizer/BioNTech
Brazil 297,960,460 1,422.5 61.3% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Indonesia 230,610,233 861.6 34.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Japan 196,576,395 1,553.6 76.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Mexico 131,601,135 1,042.9 51.2% CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Russia 124,400,024 852.4 38% EpiVacCorona, Sputnik V
Pakistan 122,319,215 576.4 23.5% CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Germany 120,376,028 1,451.6 68.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Turkey 119,987,705 1,457.6 61.1% Pfizer/BioNTech, Sinovac
United Kingdom 113,910,449 1,713.2 69.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Vietnam 110,917,609 1,160.9 45.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
France 103,028,188 1,538.0 69.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Iran 102,145,229 1,216.1 53.3% Covaxin, COVIran Barekat, Oxford/AstraZeneca, Sinopharm/Beijing, Soberana02, Sputnik V
Italy 95,107,638 1,573.8 72.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bangladesh 92,730,087 574.7 22.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Thailand 90,735,069 1,306.9 57.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
South Korea 84,150,239 1,629.7 79% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Philippines 78,528,357 736.3 41.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Spain 75,173,640 1,608.9 80.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 67,104,574 1,508.2 65.2% CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Canada 60,284,289 1,626.7 78.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Colombia 53,986,327 1,087.4 47.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Malaysia 52,384,615 1,625.5 77.7% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Morocco 48,614,680 1,349.3 62.8% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Saudi Arabia 47,265,454 1,402.5 66.3% Oxford/AstraZeneca, Pfizer/BioNTech
Poland 41,183,099 1,084.4 53.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 40,049,234 2,138.3 85.1% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Peru 39,183,058 1,224.9 53.4% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Australia 39,011,295 1,560.9 74.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Egypt 36,906,765 360.6 13.7% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik V
Uzbekistan 32,803,308 995.4 17.9% Moderna, Oxford/AstraZeneca, Sputnik V, ZF2001
Taiwan 30,648,405 1,298.1 52.9% Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sri Lanka 29,644,331 1,368.0 63.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Cambodia 28,564,675 1,757.8 81.7% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Cuba 27,872,484 2,458.3 79.8% Abdala, Soberana02
South Africa 25,238,789 436.8 24.7% Johnson&Johnson, Pfizer/BioNTech
Netherlands 24,455,078 1,419.2 73.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Ukraine 24,054,784 539.1 24.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Ecuador 23,857,066 1,396.4 62.9% CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Venezuela 23,156,914 802.1 32.1% Abdala, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
United Arab Emirates 21,548,528 2,187.6 89.7% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Belgium 17,080,315 1,495.4 76% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kazakhstan 16,715,042 914.6 43.9% QazVac, Sinopharm/Beijing, Sputnik V
Nepal 16,536,009 588.7 27.1% Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Portugal 16,308,391 1,586.1 86.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Israel 16,137,958 1,816.6 65% Moderna, Pfizer/BioNTech
Sweden 15,644,748 1,536.3 69% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Romania 14,650,539 752.3 37.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Greece 14,046,041 1,309.3 61.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Dominican Republic 13,759,792 1,294.8 52.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Hungary 13,598,032 1,392.0 59.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Austria 13,412,688 1,516.1 66.5% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Czechia 13,337,002 1,255.2 59.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Switzerland 11,663,275 1,369.5 66.6% Moderna, Pfizer/BioNTech
Iraq 11,380,981 296.1 11.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Azerbaijan 10,426,930 1,048.7 45.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Tunisia 10,376,040 897.2 43.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Singapore 10,094,499 1,790.2 83.4% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Algeria 9,989,662 236.6 9.9% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Mozambique 9,706,476 329.1 11.7% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Denmark 9,681,985 1,670.0 76.7% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nigeria 9,640,048 49.2 1.8% Oxford/AstraZeneca
Guatemala 9,619,772 557.7 22.4% Moderna, Oxford/AstraZeneca
Hong Kong 9,367,531 1,239.1 59.8% Pfizer/BioNTech, Sinovac
El Salvador 9,096,086 1,416.7 62.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Angola 9,026,310 293.0 9% Oxford/AstraZeneca
Myanmar 9,001,616 167.6 6.5% Oxford/AstraZeneca, Sinopharm/Beijing
Rwanda 8,748,557 711.2 24.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Norway 8,563,552 1,611.4 71.8% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Finland 8,299,932 1,504.1 72.8% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Ireland 8,026,966 1,653.8 77.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Ethiopia 8,005,606 73.3 1.3% Oxford/AstraZeneca
Bolivia 7,943,468 699.7 34.5% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Honduras 7,916,340 825.7 41% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Jordan 7,822,828 785.7 37.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Serbia 7,752,661 1,110.4 44.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
New Zealand 7,441,877 1,523.3 73.1% Pfizer/BioNTech
Costa Rica 7,034,279 1,407.0 62.9% Oxford/AstraZeneca, Pfizer/BioNTech
Kenya 6,811,043 132.5 5.1% Oxford/AstraZeneca, Sputnik V
Uruguay 6,781,619 1,966.1 77% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Zimbabwe 6,544,331 453.2 19.3% Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Paraguay 5,921,882 851.3 36.8% Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Oman 5,822,656 1,205.6 56.6% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Belarus 5,685,092 599.4 25.6% Sinopharm/Beijing, Sputnik V
Panama 5,601,919 1,341.2 58.1% Oxford/AstraZeneca, Pfizer/BioNTech
Tajikistan 5,059,324 555.9 25% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Slovakia 4,959,747 910.5 43% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Qatar 4,954,143 1,781.0 79.8% Moderna, Pfizer/BioNTech
Uganda 4,751,422 111.2 2.1% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Mongolia 4,408,998 1,390.8 67.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Laos 4,402,770 605.1 38.2% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Croatia 4,073,744 996.2 46.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Afghanistan 4,018,197 108.1 8.6% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Cote d'Ivoire 3,845,788 153.4 4.7% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Lithuania 3,665,245 1,313.9 63.6% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Lebanon 3,566,507 520.7 24.4% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Ghana 3,493,688 117.4 2.8% Oxford/AstraZeneca, Sputnik V
Bulgaria 3,283,897 467.5 24.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kuwait 3,100,000 749.3 0.9% Pfizer/BioNTech
Palestine 2,974,583 583.1 26.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Bahrain 2,894,455 1,844.3 73.7% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Slovenia 2,642,406 1,278.1 55.3% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Guinea 2,443,497 196.8 6.4% Sputnik V
Libya 2,274,790 340.6 9.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Latvia 2,177,752 1,130.4 61% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Georgia 2,133,935 571.9 26.5% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Albania 2,081,782 726.3 33.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Kyrgyzstan 1,986,976 314.6 14% Sinopharm/Beijing, Sputnik V
Senegal 1,959,198 123.6 5.5% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Mauritius 1,827,407 1,444.2 69.4% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Mauritania 1,734,046 393.8 15.3% Oxford/AstraZeneca, Sinopharm/Beijing
North Macedonia 1,675,793 804.5 37.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Sudan 1,659,666 39.7 0.3% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Kosovo 1,609,325 872.1 41.1% Oxford/AstraZeneca, Pfizer/BioNTech
Moldova 1,607,196 453.3 26.1% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Togo 1,507,722 191.1 6.5% Oxford/AstraZeneca
Estonia 1,474,767 1,116.5 59.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Malawi 1,353,479 74.6 3.2% Johnson&Johnson, Oxford/AstraZeneca
Botswana 1,352,557 600.0 20.8% Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Syria 1,342,360 76.7 4.1% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Nicaragua 1,306,694 202.1 5.6% Abdala, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Soberana02, Sputnik Light, Sputnik V
Cyprus 1,298,388 1,025.0 45.9% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Trinidad and Tobago 1,281,756 922.2 46.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Bosnia and Herzegovina 1,242,203 373.7 15.3% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Fiji 1,213,236 1,373.2 65.6% Oxford/AstraZeneca
Armenia 1,110,891 376.3 12.6% Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Jamaica 1,095,662 373.3 17.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Zambia 1,040,604 60.0 3.8% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Bhutan 1,010,129 1,339.0 63.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Niger 963,041 42.9 2% Oxford/AstraZeneca, Sinopharm/Beijing
Malta 942,729 1,949.7 89.3% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Macao 906,441 1,435.1 67.7% Pfizer/BioNTech, Sinopharm/Beijing
Luxembourg 877,632 1,444.1 59.2% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cameroon 859,760 34.1 2% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Maldives 763,252 1,480.0 70.2% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Yemen 759,220 26.6 1.2% Johnson&Johnson, Oxford/AstraZeneca, Sinovac
Brunei 744,337 1,602.5 73.6% Oxford/AstraZeneca, Sinopharm/Beijing
Somalia 681,532 45.4 2.1% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Guyana 668,046 857.6 34.8% Oxford/AstraZeneca, Sputnik V
Burkina Faso 661,796 31.8 1.4% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Namibia 649,840 265.4 12% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Iceland 637,380 1,802.7 79.4% Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Mali 627,924 32.9 1.5% Oxford/AstraZeneca
Madagascar 625,884 23.8 1.6% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Congo 625,579 7.4 0.2% Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Sierra Leone 617,851 80.8 3.3% Oxford/AstraZeneca, Sinopharm/Beijing
Lesotho 617,671 293.0 27.2% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Northern Cyprus 617,389 1,657.5 74.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Liberia 589,628 122.4 9.5% Oxford/AstraZeneca
Tanzania 560,938 10.0 1% Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing
Cape Verde 539,908 971.1 42.5% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Montenegro 525,661 844.6 40.7% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Comoros 476,350 572.3 23.8% Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Suriname 473,832 822.6 37.7% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Equatorial Guinea 443,135 338.5 15% Sinopharm/Beijing
Papua New Guinea 435,991 50.7 2.1% Oxford/AstraZeneca
Central African Republic 422,496 90.5 6.9% Covaxin, Oxford/AstraZeneca
Belize 403,528 1,053.4 49.8% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Benin 383,501 33.4 2.6% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Guinea-Bissau 365,089 194.8 1% Oxford/AstraZeneca, Sinopharm/Beijing
New Caledonia 347,129 1,191.4 57.5% Pfizer/BioNTech
French Polynesia 314,576 1,132.9 55.3% Johnson&Johnson, Pfizer/BioNTech
Barbados 287,286 1,002.3 46.9% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Eswatini 286,670 252.3 21.1% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Gabon 277,979 131.2 5.3% Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Bahamas 274,502 711.8 34.9% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Gambia 268,008 117.5 9.8% Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Chad 249,651 16.1 0.5% Sinopharm/Beijing
Samoa 223,504 1,139.6 44% Oxford/AstraZeneca
South Sudan 218,154 19.9 1.2% Johnson&Johnson, Oxford/AstraZeneca
Curacao 197,381 1,234.8 59.3% Moderna, Pfizer/BioNTech
Solomon Islands 193,817 296.9 6.6% Oxford/AstraZeneca
Jersey 181,102 1,680.0 69.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Seychelles 175,390 1,812.6 80.1% Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Democratic Republic of Congo 167,791 2.0 0.1% Oxford/AstraZeneca
Aruba 161,593 1,526.7 73.7% Pfizer/BioNTech
Haiti 158,479 14.2 0.5% Johnson&Johnson, Moderna
Isle of Man 133,094 1,583.0 77.1% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Vanuatu 129,582 442.7 13.7% Oxford/AstraZeneca
Cayman Islands 121,080 1,886.7 86.3% Oxford/AstraZeneca, Pfizer/BioNTech
Tonga 116,753 1,104.6 41.7% Oxford/AstraZeneca
Antigua and Barbuda 115,487 1,199.4 56.8% Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Sao Tome and Principe 114,251 541.4 15.2% Oxford/AstraZeneca
Guernsey 104,131 1,660.6 21.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bermuda 101,341 1,584.2 74% Oxford/AstraZeneca, Pfizer/BioNTech
Saint Lucia 100,165 550.7 25.3% Oxford/AstraZeneca, Pfizer/BioNTech
Djibouti 99,679 103.9 2.7% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Gibraltar 96,771 2,870.0 118.1% Pfizer/BioNTech
Greenland 77,655 1,386.1 66.8% Moderna, Pfizer/BioNTech
Grenada 73,320 657.8 30.2% Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Dominica 55,134 769.8 37.1% Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Saint Vincent and the Grenadines 52,736 478.5 20% Oxford/AstraZeneca
Sint Maarten (Dutch part) 51,432 1,265.1 60.7% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Saint Kitts and Nevis 51,414 966.0 46.2% Oxford/AstraZeneca, Pfizer/BioNTech
Liechtenstein 50,171 1,323.4 65.7% Moderna, Pfizer/BioNTech
Monaco 49,980 1,292.1 60.3% Pfizer/BioNTech
Turks and Caicos Islands 49,107 1,303.8 62.4% Pfizer/BioNTech
San Marino 47,100 1,394.1 72.3% Pfizer/BioNTech, Sputnik V
Turkmenistan 41,993 7.0 0.2% EpiVacCorona, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Anguilla 19,066 1,055.4 50.7% Oxford/AstraZeneca, Pfizer/BioNTech
Andorra 19,064 247.6 1.6% Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nauru 14,784 1,163.7 57.1% Oxford/AstraZeneca
Wallis and Futuna 11,903 752.9 37.3% Moderna
Bonaire Sint Eustatius and Saba 7,391 275.7 6.2% Moderna, Pfizer/BioNTech
Falkland Islands 4,322 1,070.1 42.5% Oxford/AstraZeneca
Montserrat 1,306 243.7 3.6% Oxford/AstraZeneca

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out. View the Covid-19 vaccination world map below.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 44

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of Covid-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
10 Nov, 2021: Complete Approval given by Japan
9 Nov, 2021: Complete Approval given by Canada
29 Oct, 2021: Emergency Use Authorization given by US
12 Oct, 2021: Emergency Use Authorization given by Australia
8 Oct, 2021: Emergency Use Authorization given by Malaysia
22 Sep, 2021: Emergency Use Authorization given by US
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
21 Mar, 2021: Emergency Use Authorization given by Libya
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 30

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of Covid-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
12 Nov, 2021: Complete Approval given by Canada
20 Oct, 2021: Emergency Use Authorization given by the US
5 Oct, 2021: Emergency Use Authorization given by EU
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
21 Mar, 2021: Emergency Use Authorization given by Libya
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 52

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, and schedule. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
21 Mar, 2021: Emergency Use Authorization given by Libya
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 1

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
1 Nov, 2021: Emergency Use Authorization given by Indonesia
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 32

Adenoviral vaccine able to confer nearly 70% protection against all Covid-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
21 Oct, 2021: Emergency Use Authorization given by the US
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
21 Mar, 2021: Emergency Use Authorization given by Libya
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Gamaleya - Sputnik V 33,758 2 2 - 8°C 91.4% 77

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all COVID-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
31 Oct, 2021: Emergency Use Authorization given by Cambodia
25 Aug, 2021: Emergency Use Authorization given by Indonesia
21 Jul, 2021: Emergency Use Authorization given by Chile
15 Jul, 2021: Emergency Use Authorization given by Nigeria
24 Jun, 2021: Emergency Use Authorization given by Oman
5 Jun, 2020: Conditional Approval given by Brazil
15 May, 2021: Emergency Use Authorization given by Republic of Ecuador
13 May, 2021: Emergency Use Authorization given by Maldives
30 Apr, 2021: Emergency Use Authorization given by Turkey
30 Apr, 2021: Emergency Use Authorization given by Albania
27 Apr, 2021: Emergency Use Authorization given by Bangladesh
20 Apr, 2021: Emergency Use Authorization given by Nepal
12 Apr, 2021: Emergency Use Authorization given by India
1 Apr, 2021: Emergency Use Authorization given by Panama
30 Mar, 2021: Emergency Use Authorization given by Mali
26 Mar, 2021: Emergency Use Authorization given by Antigua
26 Mar, 2021: Emergency Use Authorization given by Barbuda
23 Mar, 2021: Emergency Use Authorization given by Vietnam
22 Mar, 2021: Emergency Use Authorization given by Mauritius
19 Mar, 2021: Emergency Use Authorization given by Cameroon
19 Mar, 2021: Emergency Use Authorization given by Philippines
19 Mar, 2021: Emergency Use Authorization given by Republic of Seychelles
12 Mar, 2021: Emergency Use Authorization given by Azerbaijan
11 Mar, 2021: Emergency Use Authorization given by Namibia
10 Mar, 2021: Emergency Use Authorization given by Jordan
10 Mar, 2021: Emergency Use Authorization given by Kenya
10 Mar, 2021: Emergency Use Authorization given by Morocco
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
7 Mar, 2021: Emergency Use Authorization given by Macedonia
7 Mar, 2021: Emergency Use Authorization given by North Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
4 Mar, 2021: Emergency Use Authorization given by Iraq
4 Mar, 2021: Emergency Use Authorization given by Laos
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
26 Feb, 2021: Emergency Use Authorization given by Republic of Moldova
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
23 Feb, 2021: Emergency Use Authorization given by Kyrgyzstan
23 Feb, 2021: Emergency Use Authorization given by Guyana
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
12 Feb, 2021: Emergency Use Authorization given by Saint Vincent and the Grenadines
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
9 Feb, 2021: Emergency Use Authorization given by Mongolia
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
14 Jan, 2021: Temporary Registration given by Kazakhstan
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
31 Dec, 2020: Emergency Use Authorization given by Serbia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: Complete Approval given by Russia
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.7% 28

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
12 Nov, 2021: Emergency Use Authorization given by Pakistan
1 Oct, 2021: Emergency Use Authorization given by Malaysia
9 Sep, 2021: Emergency Use Authorization given by Chile
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
17 Jul, 2021: Emergency Use Authorization given by Sri Lanka
3 Jul, 2021: Emergency Use Authorization given by South Africa
24 Jun, 2021: Emergency Use Authorization given by Oman
11 Jun, 2021: Emergency Use Authorization given by China
6 Jun, 2021: Emergency Use Authorization given by Bangladesh
4 Jun, 2021: Emergency Use Authorization given by Nepal
2 Jun, 2021: Emergency use listing (EUL) given by WHO
27 Apr, 2021: Emergency Use Authorization given by Egypt
10 Apr, 2021: Emergency Use Authorization given by Pakistan
9 Apr, 2021: Emergency Use Authorization given by Panama
10 Mar, 2021: Complete Approval given by Ukraine
10 Mar, 2021: Emergency Use Authorization given by Zimbabwe
05 Mar, 2021: Complete Approval given by Tunisia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Hong Kong
26 Feb, 2021: Emergency Use Authorization given by Ecuador
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
6 Feb, 2021: Emergency Use Authorization given by Lao People's Democratic Republic
6 Feb, 2021: Emergency Use Authorization given by Uruguay
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Sinopharm 60,000+ 2 2 - 8°C 86.0% 35

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 10 December 2020
Trial Start Date - 16 July 2020
Result Publication Date - 31 December 2020
12 Nov, 2021: Emergency Use Authorization given by Pakistan
2 Oct, 2021: Emergency Use Authorization given by Argentina
21 Aug, 2021: Emergency Use Authorization given by Mexico
25 Aug, 2021: Emergency Use Authorization given by Saudi Arabia
24 Aug, 2021: Emergency Use Authorization given by Nigeria
19 Aug, 2021: Emergency Use Authorization given by Kenya
16 Jul, 2021: Emergency Use Authorization given by Malaysia
12 Jul, 2021: Emergency Use Authorization given by Tunisia
9 Jul, 2021: Emergency Use Authorization given by Trinidad and Tobago
18 Jun, 2021: Emergency Use Authorization given by Gambia
11 Jun, 2021: Emergency Use Authorization given by China
7 Jun, 2021: Emergency Use Authorization given by Philippines
4 June, 2021: Emergency Use Authorization given by Vietnam
2 Jun, 2021: Emergency Use Authorization given by Zambia
29 May, 2021: Emergency Use Authorization given by Bangladesh
28 May, 2021: Emergency Use Authorization given by Thailand
07 May, 2021: Emergency Use Authorization given by WHO
29 Apr, 2021: Emergency Use Authorization given by Indonesia
20 Mar, 2021: Emergency Use Authorization given by Sri Lanka
16 Mar, 2021: Emergency Use Authorization given by Maldives
11 Mar, 2021: Emergency Use Authorization given by Iran
9 Mar, 2021: Emergency Use Authorization given by Zimbabwe
1 Mar, 2021: Emergency Use Authorization given by Venezuela
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
18-Feb, 2021: Emergency Use Authorization given by Nepal
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 9

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all COVID-19 and 90% efficacy in preventing severe COVID-19 with just a single dose.

07 Sep, 2021: Emergency Use Authorization given by Indonesia
16 Jun, 2021: Complete approval given by Ecuador
15 Jun, 2021: Emergency Use Authorization given by Malaysia
12 Jun, 2021: Emergency Use Authorization given by Argentina
8 Apr, 2021: Emergency Use Authorization given by Chile
22 Mar, 2021: Emergency Use Authorization given by Hungary
12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Trial Start Date - 15 September 2020
Today

Bharat Biotech 25,800 2 2 - 8°C 81.0% 7

Adjuvanted inactivated vaccine produced in Vero cells and developed by India, showed 81% efficacy in preventing COVID-19 after two doses.

3 Nov, 2021: Emergency Use Authorization given by WHO
12 Oct, 2021: Emergency Use Authorization given by India
20 Apr, 2021: Emergency Use Authorization given by Philippines
6 Apr, 2021: Emergency Use Authorization given by Mexico
26 Mar, 2021: Complete Approval given by Mauritius
21 Mar, 2021: Emergency Use Authorization given by Nepal
04 Mar, 2021: Emergency Use Authorization given by Zimbabwe
19 Feb, 2021: Emergency Use Authorization given by Iran
3 Jan, 2021: Restricted Emergency Use Authorization given by India
Trial Start Date - 16 November 2020
Today

Gamaleya - Sputnik Light 110 1 2 - 8°C 79.4% 18

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, showed 79.4% efficacy from 28 days after the injection was administered as part of Russia’s mass vaccination program.

31 Oct, 2021: Emergency Use Authorization given by Cambodia
6 Oct, 2021: Emergency Use Authorization given by UAE
24 Sep, 2021: Emergency Use Authorization given by Egypt
16 Sep, 2021: Emergency Use Authorization given by Iran
06 Sep, 2021: Complete Approval given by Armenia
23 Aug, 2021: Emergency Use Authorization given by Philippines
15 Jul, 2021: Complete Approval given by Kazakhstan
25 Jun, 2021: Emergency Use Authorization given by Kyrgyzstan
11 Jun, 2021: Emergency Use Authorization given by Mongolia
7 Jun, 2021: Emergency Use Authorization given by Republic of the Congo
3 Jun, 2021: Emergency Use Authorization given by Belarus
2 Jun, 2021: Emergency Use Authorization given by Mauritius
31 May, 2021: Emergency Use Authorization given by Palestine
21 May, 2021: Emergency Use Authorization given by Nicaragua
15 May, 2021: Emergency Use Authorization given by Venezuela
12 May, 2021: Emergency Use Authorization given by Angola
11 May, 2021: Emergency Use Authorization given by Bahrain
6 May, 2021: Complete Approval given by Russia
Trial Start Date - 15 January 2021
Today

Cadila Healthcare Ltd - ZyCoV-D 28,000+ 3 2 - 8°C 66.6% 1

ZyCoV-D is the first plasmid DNA, needle-free vaccine against COVID-19, showing 66.6% efficacy after the third injection was administered in over 28,000 volunteers at more than 50 clinical sites spread across India.

20 Aug, 2021: Emergency Use Authorization given by India
Trial Start Date - 20 January 2021
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)